RxDoctor Payments Data

Deepmala Nandanwar, MD

Neurology · Fountain Valley, CANPI 1942685094

Payments from drug & device makers

$27,184in general payments, 2019–2025

Across 840 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • AbbVie$3K
  • Acadia Pharmaceuticals Inc$1K
  • MDD US Operations, LLC$1K
  • Neurocrine Biosciences, Inc.$1K
  • UCB, Inc.$1K
  • plus $10K from 42 others

What the payments were for

  • Grants$10,00037%
  • Travel & lodging$3821%
  • Food & beverage$16,72862%
  • Education$740%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,184 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$51,302
Medicare patients
100
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl39$171,103
NuplazidPimavanserin Tartrate13$65,843
RytaryCarbidopa/Levodopa67$56,941
InbrijaLevodopa18$46,807
UbrelvyUbrogepant15$19,903
QuliptaAtogepant16$18,966
Rasagiline Mesylate32$10,220
HorizantGabapentin Enacarbil15$7,367
LinzessLinaclotide11$6,330
Carbidopa-LevodopaCarbidopa/Levodopa206$5,835
Entacapone27$4,984
Memantine Hcl ErMemantine Hcl33$3,376
AmantadineAmantadine Hcl41$2,797
Carbidopa14$1,906
Donepezil Hcl104$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$1,234$171,10339 claims
Acadia Pharmaceuticals IncNuplazid$1,303$65,84313 claims
Amneal Pharmaceuticals LLCRytary$583$56,94167 claims
Acorda Therapeutics, IncInbrija$144$46,80718 claims
AbbVieUbrelvy, Qulipta, Linzess$2,656$45,19942 claims
Arbor Pharmaceuticals, Inc.Horizant$65$7,36715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →